These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6464416)

  • 1. A rare example of weakened expression of the Kell (K1) antigen.
    Kline WE; Sullivan CM; Bowman RJ
    Vox Sang; 1984; 47(2):170-3. PubMed ID: 6464416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unusual suppression of Kell system antigens in a healthy blood donor.
    Norman PC; Daniels GL
    Transfusion; 1988; 28(5):460-2. PubMed ID: 3420674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Kmod blood group phenotype in a healthy individual.
    Winkler MM; Beattie KM; Cisco SL; Sigmund KE; Johnson CL; Rabin BI; Marsh WL
    Transfusion; 1989 Sep; 29(7):642-5. PubMed ID: 2773032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An individual with McLeod syndrome and the Kell blood group antigen K(K1).
    Marsh WL; Schnipper EF; Johnson CL; Mueller KA; Schwartz SA
    Transfusion; 1983; 23(4):336-8. PubMed ID: 6879675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new low-incidence antigen in the Kell blood group system: VLAN (KEL25).
    Jongerius JM; Daniels GL; Overbeeke MA; Petty AC; Reid M; Oyen R; Rijksen H; van Leeuwen EF
    Vox Sang; 1996; 71(1):43-7. PubMed ID: 8837356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary acanthocytosis associated with the McLeod phenotype of the Kell blood group system.
    Symmans WA; Shepherd CS; Marsh WL; Oyen R; Shohet SB; Linehan BJ
    Br J Haematol; 1979 Aug; 42(4):575-83. PubMed ID: 476009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K22, a 'new' para-Kell antigen of high frequency.
    Bar Shany S; Ben Porath D; Levene C; Sela R; Daniels GL
    Vox Sang; 1982 Feb; 42(2):87-90. PubMed ID: 7064432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel variant of the human blood group K1 antigen.
    Skradski K; Reid ME; Mount M; Polesky HF; Sausais L; Yacob M; Batts R
    Vox Sang; 1994; 66(1):68-71. PubMed ID: 8146986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Km in a transfused man with McLeod syndrome.
    White W; Washington ED; Sabo BH; Stroup M; McCreary J; Oyen R; Marsh WL
    Rev Fr Transfus Immunohematol; 1980; 23(3):305-17. PubMed ID: 7406997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rare blood donors with irregular antibodies].
    Milanović MK; Bujandrić N; Knezević NM
    Med Pregl; 2013; 66(7-8):331-4. PubMed ID: 24069817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A family with unusual Kell genotypes.
    Walsh TJ; Daniels GL; Tippett P
    Forensic Sci Int; 1981; 18(2):161-3. PubMed ID: 7297967
    [No Abstract]   [Full Text] [Related]  

  • 12. K23. A low-incidence antigen in the Kell blood group system identified by biochemical characterization.
    Marsh WL; Redman CM; Kessler LA; DiNapoli J; Scarborough AL; Philipps AG; Mody KM
    Transfusion; 1987; 27(1):36-40. PubMed ID: 3810821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Day phenotype: a "new" variant in the Kell blood group system.
    Brown A; Berger R; Lasko D; Brokenshire D; Humphreys J; Stout T; Moore BP; Johnson CL; Mueller KA; Marsh WL
    Rev Fr Transfus Immunohematol; 1982 Dec; 25(6):619-27. PubMed ID: 7170568
    [No Abstract]   [Full Text] [Related]  

  • 14. [Exclusion of paternity based on the Kell-cellano blood group system and family pedigree studies].
    Hölgyéné VZ; Szabó A
    Morphol Igazsagugyi Orv Sz; 1986 Oct; 26(4):288-90. PubMed ID: 3785246
    [No Abstract]   [Full Text] [Related]  

  • 15. Transfusion support for a patient with McLeod phenotype without chronic granulomatous disease and with antibodies to Kx and Km.
    Bansal I; Jeon HR; Hui SR; Calhoun BW; Manning DW; Kelly TJ; Lee S; Baron BW
    Vox Sang; 2008 Apr; 94(3):216-220. PubMed ID: 18167163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a defect in the intracellular trafficking of a Kell blood group variant.
    Yazdanbakhsh K; Lee S; Yu Q; Reid ME
    Blood; 1999 Jul; 94(1):310-8. PubMed ID: 10381527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of Kell-active protein from the red cell membrane.
    Redman CM; Marsh WL; Mueller KA; Avellino GP; Johnson CL
    Transfusion; 1984; 24(2):176-8. PubMed ID: 6200970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel KEL*1,3 allele with weak Kell antigen expression confirming the cis-modifier effect of KEL3.
    Körmöczi GF; Scharberg EA; Gassner C
    Transfusion; 2009 Apr; 49(4):733-9. PubMed ID: 19347978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fetal erythroblastosis in Kell incompatibility].
    Fuith LC; Bichler A; Schönitzer D
    Geburtshilfe Frauenheilkd; 1987 Feb; 47(2):131-3. PubMed ID: 3471624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological changes associated with the McLeod phenotype of the Kell blood group system.
    Wimer BM; Marsh WL; Taswell HF; Galey WR
    Br J Haematol; 1977 Jun; 36(2):219-24. PubMed ID: 871435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.